Literature DB >> 1536800

Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome.

P D Jensen1, I M Jensen, J Ellegaard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1536800     DOI： 10.1111/j.1365-2141.1992.tb06411.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.

Authors:  Emanuela Messa; Sonia Carturan; Chiara Maffè; Marisa Pautasso; Enrico Bracco; Antonella Roetto; Francesca Messa; Francesca Arruga; Ilaria Defilippi; Valentina Rosso; Chiara Zanone; Antonia Rotolo; Elisabetta Greco; Rosa M Pellegrino; Daniele Alberti; Giuseppe Saglio; Daniela Cilloni
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

Review 2.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 3.  Optimal management strategies for chronic iron overload.

Authors:  James C Barton
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Authors:  Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Michael Stadler; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Andrea Marcellari; Bernard Roubert; Christian Rose
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

5.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

6.  Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome.

Authors:  Maha A Badawi; Linda M Vickars; Jocelyn M Chase; Heather A Leitch
Journal:  Adv Hematol       Date:  2010-03-23

Review 7.  Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea.

Authors:  Jong Wook Lee
Journal:  Int J Hematol       Date:  2008-07-05       Impact factor: 2.490

8.  Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.

Authors:  Harpreet Kochhar; Chantal S Leger; Heather A Leitch
Journal:  Case Rep Hematol       Date:  2015-03-30

9.  Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up.

Authors:  Salvatore Improta; Maria Rosaria Villa; Antonio Volpe; Angela Lombardi; Paola Stiuso; Nicola Cantore; Lucia Mastrullo
Journal:  Oncol Lett       Date:  2013-10-10       Impact factor: 2.967
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.